Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.
Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1
A key member of the team that developed bone marrow transplantation as a successful treatment for leukemia nearly half a century ago, Frederick Appelbaum, MD, was honored on Feb. 18 with a Lifetime Achievement Award from the American Society for Transplantation and Cellular Therapy at the organization’s annual meeting in Orlando, Florida.
The Global Community of Hematopoietic Cell Transplantation and Cellular Therapy Specialists will Gather for the 2023 Tandem Meetings to Improve the Lives.